1. Home
  2. SCOR vs KLRS Comparison

SCOR vs KLRS Comparison

Compare SCOR & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo comScore Inc.

SCOR

comScore Inc.

HOLD

Current Price

$7.28

Market Cap

101.6M

ML Signal

HOLD

Logo Kalaris Therapeutics Inc.

KLRS

Kalaris Therapeutics Inc.

HOLD

Current Price

$4.05

Market Cap

113.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCOR
KLRS
Founded
1999
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
101.6M
113.0M
IPO Year
2007
2020

Fundamental Metrics

Financial Performance
Metric
SCOR
KLRS
Price
$7.28
$4.05
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$19.00
AVG Volume (30 Days)
6.3K
613.5K
Earning Date
05-05-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
127.37
75.70
EPS
N/A
N/A
Revenue
$403,549,000.00
$165,000.00
Revenue This Year
$2.75
N/A
Revenue Next Year
$7.30
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.02
N/A
52 Week Low
$6.10
$2.14
52 Week High
$10.18
$11.88

Technical Indicators

Market Signals
Indicator
SCOR
KLRS
Relative Strength Index (RSI) 47.57 47.01
Support Level $6.88 $3.96
Resistance Level $7.80 $4.40
Average True Range (ATR) 0.40 0.33
MACD -0.03 0.05
Stochastic Oscillator 39.61 69.34

Price Performance

Historical Comparison
SCOR
KLRS

About SCOR comScore Inc.

comScore Inc is a information and analytics company that measures advertising, content, and the consumer audiences of each, across media platforms. It create products using a data platform that combines information on digital platforms (connected televisions, mobile devices, tablets and computers), televisions, direct to consumer applications, and movie screens with demographics and other descriptive information. The company has developed proprietary data science that enables measurement of person-level and household-level audiences, removing duplicated viewing across devices and over time. Its segments include Content & Ad Measurement and Research & Insight Solutions of which the Content & Ad Measurement segment derives the majority of the revenue.

About KLRS Kalaris Therapeutics Inc.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Share on Social Networks: